Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib for Idiopathic Granulomatous Mastitis
NCT05852171Phase 2Active, not recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- May 2023
- Primary completion
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of baricitinib in idiopathic granulomatous mastitis (IGM), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Objective Response Rate up to 24 months. Started May 2023; status: active, not recruiting.
02
Drugs
baricitinib
03
Conditions
idiopathic granulomatous mastitis (IGM)
Beyond the preview
Go deeper on NCT05852171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05852171.